S
Sven Hoffner
Researcher at Swedish Institute
Publications - 32
Citations - 2609
Sven Hoffner is an academic researcher from Swedish Institute. The author has contributed to research in topics: Tuberculosis & Mycobacterium tuberculosis. The author has an hindex of 21, co-authored 32 publications receiving 2453 citations. Previous affiliations of Sven Hoffner include University of the Sciences.
Papers
More filters
Journal ArticleDOI
Emergence of New Forms of Totally Drug-Resistant Tuberculosis Bacilli: Super Extensively Drug-Resistant Tuberculosis or Totally Drug-Resistant Strains in Iran
Ali Akbar Velayati,Mohammad Reza Masjedi,Parissa Farnia,Payam Tabarsi,Jalladein Ghanavi,Abol Hassan ZiaZarifi,Sven Hoffner +6 more
TL;DR: In this article, the emergence of resistant bacilli (totally drug-resistant [TDR] or super extensively drug resistant [XDR] tuberculosis [TB] strains) among patients with multidrug-resistant TB (MDR-TB) was documented.
Journal ArticleDOI
Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance
Abigail Wright,Matteo Zignol,Armand Van Deun,Armand Van Deun,Dennis Falzon,Sabine Ruesch Gerdes,Knut Feldman,Sven Hoffner,Francis Drobniewski,Lucía Barrera,Dick van Soolingen,Fadila Boulabhal,CN Paramasivan,KM Kam,Satoshi Mitarai,Paul Nunn,Mario C. Raviglione +16 more
TL;DR: The prevalence of multidrug-resistant tuberculosis in new cases increased substantially in South Korea and in Tomsk Oblast and Orel Oblast, Russia, but was stable in Estonia and Latvia, and the prevalence of MDR tuberculosis in all tuberculosis cases decreased in Hong Kong and the USA.
Journal ArticleDOI
Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance
Abigail L. Manson,Keira A. Cohen,Keira A. Cohen,Thomas Abeel,Thomas Abeel,Christopher A. Desjardins,Derek T. Armstrong,Clifton E. Barry,Jeannette Brand,Sinéad B. Chapman,Sang Nae Cho,Andrei Gabrielian,James Gomez,Andreea M. Jodals,Moses Joloba,P. Jureen,Jong Seok Lee,Lesibana Anthony Malinga,Mamoudou Maiga,Dale Nordenberg,Ecaterina Noroc,Elena Romancenco,Alex N. Salazar,Alex N. Salazar,Willy Ssengooba,Ali Akbar Velayati,Kathryn Winglee,Aksana Zalutskaya,Laura E. Via,Gail H. Cassell,Susan E. Dorman,Jerrold J. Ellner,Parissa Farnia,James E. Galagan,James E. Galagan,Alex Rosenthal,Valeriu Crudu,Daniela Homorodean,Po-Ren Hsueh,Sujatha Narayanan,Alexander S. Pym,Alena Skrahina,Soumya Swaminathan,Martie van der Walt,David Alland,William R. Bishai,Ted Cohen,Ted Cohen,Sven Hoffner,Bruce W. Birren,Ashlee M. Earl +50 more
TL;DR: Molecular diagnostics that include markers for rifampicin resistance alone will be insufficient to identify pre-MDR strains, and incorporation of knowledge of polymorphisms that occur before the emergence of multidrug resistance, particularly katG p.Ser315Thr, into molecular diagnostics should enable targeted treatment of patients with pre-mDR-TB to prevent further development of MDR- TB.
Journal ArticleDOI
Spread of Drug-Resistant Pulmonary Tuberculosis in Estonia
Annika Krüüner,Annika Krüüner,Sven Hoffner,Heinart Sillastu,Manfred Danilovits,Klavdia Levina,Stefan B. Svenson,Solomon Ghebremichael,Tuija Koivula,Tuija Koivula,Gunilla Källenius,Gunilla Källenius +11 more
TL;DR: Restriction fragment length polymorphism (RFLP) analysis of 209Mycobacterium tuberculosis clinical isolates obtained from newly detected pulmonary tuberculosis patients in Estonia during 1994 showed that 61 isolates belonged to a genetically closely related group of isolates, family A, with a predominant IS6110 banding pattern.
Journal ArticleDOI
Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors
Alena Skrahina,Henadz Hurevich,Aksana Zalutskaya,Evgeni Sahalchyk,Andrei Astrauko,Sven Hoffner,Valiantsin Rusovich,Andrei Dadu,Pierpaolo de Colombani,Masoud Dara,Wayne van Gemert,Matteo Zignol +11 more
TL;DR: MDR-TB is very common among TB patients throughout Belarus and the numerous risk factors identified call not only for stronger collaboration between TB and HIV control programmes, but also for the implementation of innovative measures to accelerate the detection of TB resistance and improve treatment adherence.